Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

James Larkin; Michele Del Vecchio; Paolo A Ascierto; Ivana Krajsova; Jacob Schachter; Bart Neyns; Enrique Espinosa; Claus Garbe; Vanna Chiarion Sileni; Helen Gogas; Wilson H Miller; Mario Mandalà; Geke A P Hospers; Ana Arance; Paola Queirolo; Axel Hauschild; Michael P Brown; Lada Mitchell; Luisa Veronese; Christian U Blank

首页> 外文期刊>The lancet oncology >Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

【24h】

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

机译：维拉非尼治疗BRAF（V600）突变型转移性黑色素瘤患者：一项开放性，多中心，安全性研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

F Hoffmann-La Roche.

机译：霍夫曼·拉罗什（F Hoffmann-La Roche）。

著录项

来源
《The lancet oncology》 |2014年第4期|共9页
作者
James Larkin; Michele Del Vecchio; Paolo A Ascierto; Ivana Krajsova; Jacob Schachter; Bart Neyns; Enrique Espinosa; Claus Garbe; Vanna Chiarion Sileni; Helen Gogas; Wilson H Miller; Mario Mandalà; Geke A P Hospers; Ana Arance; Paola Queirolo; Axel Hauschild; Michael P Brown; Lada Mitchell; Luisa Veronese; Christian U Blank;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. [J] . James Larkin, Michele Del Vecchio, Paolo A Ascierto, The lancet oncology . 2014,第4期

机译：维拉非尼治疗BRAF（V600）突变型转移性黑色素瘤患者：一项开放性，多中心，安全性研究。
2. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis [J] . Blank Christian U., Larkin James, Arance Ana M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：3219例BRAF（V600）突变阳性转移性黑素瘤的vemurafenib的开放标签，vemurafenib的多期安全研究：2年后续数据和长期响应者分析
3. Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience [J] . Arance A. M., Berrocal A., Lopez-Martin J. A., Clinical & translational oncology : . 2016,第11期

机译：维拉非尼在BRAF（V600）突变型转移性黑色素瘤患者中的安全性：西班牙的经验
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
6. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib [O] . Elzbieta Nowara, Joanna Huszno, Grzegorz Slomian, 2016

机译：维拉非尼治疗BRAF（V600）突变的转移性皮肤黑色素瘤患者的皮肤毒性
7. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib [O] . Elzbieta Nowara, Joanna Huszno, Grzegorz Slomian, 2016

机译：用vemurafenib治疗的BRaF（V600）突变的转移性皮肤黑素瘤患者的皮肤毒性

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

摘要

著录项

相似文献

相关主题

期刊订阅